Previous data suggest that apolipoprotein (apo) CIII may inhibit both triglyceride hydrolysis by lipoprotein lipase (LPL) and apo E-mediated uptake of triglyceride-rich lipoproteins by the liver. We studied apo B metabolism in very low density (VLDL), intermediate density (IDL), and low density lipoproteins (LDL) in two sisters with apo CiII-apo AI deficiency. The subjects had reduced levels of VLDL triglyceride, normal LDL cholesterol, and near absence of high density lipoprotein (HDL) cholesterol. Compartmental analysis of the kinetics of apo B metabolism after injection of '"I-VLDL and 131I-LDL revealed fractional catabolic rates (FCR) for VLDL apo B that were six to seven times faster than normal. Simultaneous injection of V3Hjglycerol demonstrated rapid catabolism of VLDL triglyceride. VLDL apo B was rapidly and efficiently converted to IDL and LDL. The FCR for LDL apo B was normal.
Introduction
In 1982, Norum et al. (1) reported that two sisters with extreme reductions in plasma high density lipoprotein (HDL) cholesterol and precocious coronary artery disease had deficiencies of apo-probands had low plasma levels of apo CIII and apo AI, compatible with heterozygosity in those family members. Recently, Breslow and his co-workers have characterized the genetic mutation in these young women as a 6.5 kilobase-pair translocation from the apo CIII gene to the region of the apo Al gene (2, 3) .
Although interest in this disorder was focused initially upon the link between the absence ofHDL and precocious coronary artery disease, these subjects also provided a unique opportunity to investigate the role of apo CIII in lipoprotein metabolism.
Apo CIII, a glycoprotein of molecular weight 8,500, may play an important regulatory role at two points in the metabolism ofthe triglyceride-rich lipoproteins, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) . First, in vitro studies have suggested that apo CIII inhibits the hydrolysis oftriglyceride by both lipoprotein lipase (LPL) (4, 5) and hepatic triglyceride lipase (HTGL) (6) . Second, liver perfusion studies have suggested that apo CIII inhibits the removal ofchylomicrons and VLDL by hepatocytes (7) (8) (9) . These latter results have led investigators to propose that apo CIII and apo E may have opposing roles in the regulation of the removal of triglyceride-rich lipoproteins by the liver. Both ofthe actions ofapo CIII described above would tend to prolong the residence time of VLDL in plasma and increase its concentration. Therefore, the absence of apo CIII might be associated with reduced plasma VLDL levels. The demonstration of markedly reduced plasma VLDL triglyceride concentrations in the two sisters with deficiency of apo CIII and AI (1, 10) suggested that the absence of apo CIII might have significant impact on lipoprotein metabolism.
To examine the role of apo CIII in the regulation of the metabolism of triglyceride-rich lipoproteins, we carried out studies ofthe turnover of VLDL triglyceride using [3H]glycerol, and the turnovers of VLDL, IDL, and low density lipoprotein (LDL) apo B, using '25I-VLDL and 1I'I-LDL in these two subjects without apo CIII. If apo CIII were to function by either of the mechanisms described above, the fractional removal of VLDL triglyceride from plasma would be increased in the two sisters. If the predominant role of apo CIII were the inhibition of triglyceride hydrolysis, then its absence might be associated with a rapid turnover of VLDL apo B and an efficient conversion of VLDL and IDL to LDL. On the other hand, if apo CIII had, as its major effect, the inhibition of hepatic uptake of remnants of VLDL and IDL catabolism, then its absence might be associated with a rapid turnover of VLDL apo B associated with minimal conversion of apo B in VLDL and IDL to LDL. The results of our studies, although not eliminating a role for apo CIII in the regulation of hepatic catabolism of VLDL remnants in normal subjects, indicate that apo CIII plays a significant role in vivo in the regulation of LPL-mediated hydrolysis of lipoprotein triglyceride.
Methods
Subjects. The clinical characteristics and case histories of the two subjects have been described in detail previously (1) . At the time of study, Subjects 1 and 2 were 34 and 32 yr of age, respectively. Both subjects had evidence of stable coronary artery disease, but were able to carry out routine daily activities without difficulty. Subject 1 was receiving propranolol and nitrates, whereas subject 2 was taking digoxin and furosemide. In both cases, treatment regimens had been stable for several months prior to study and were continued during the study period. Neither subject had hepatic, renal, or thyroid disease. Both individuals were on a low fat, low cholesterol diet and this was maintained during the studies (see below). Informed consent was obtained from each subject and the studies were approved by the Institutional Review Board at our institution.
Turnover protocols. Each subject underwent plasmapheresis of 2 U ofblood 1 wk before admission to the General Clinical Research Center. On admission, the patients were placed on a solid food diet consisting of 50% carbohydrate, 30% fat, and 20% protein with a ratio of polyunsaturated to saturated fat of 1.0 and 150 mg of cholesterol per day. This diet was based on a history of what their intake had been at home. At midnight, on the second day, the subjects were switched to a liquidformula diet consisting of 75% carbohydrate and 25% protein. This formula, which was consumed every 3 h, provided 60% ofthe daily maintenance calories and enabled us to maintain steady-state plasma triglyceride concentrations during the VLDL turnover study without introducing dietary fat (I 1). The morning after initiation of the liquid-formula feedings, each subject received an intravenous injection of autologous '25I-VLDL (50,MCi) and [2-3H] glycerol (300 MCi). Eighteen timed blood samples were obtained during the next 48 h. After the 48-h sample, each patient received an intravenous injection of autologous 13'I-LDL (25 ,MCi). The subjects were returned to their full-calorie solid-food diets at this time, and blood samples were obtained at specified intervals during the next 14 d. A saturated solution ofpotassium iodide was administered for the duration of the study and for an additional 2 wk to prevent thyroidal uptake of radioactive iodide.
An aliquot of '25I-VLDL used in the study of subject 1 was injected into a cynomolgus monkey along with '31I-VLDL obtained from a normal control subject. Timed blood samples were obtained during the following 20 h. VLDL, IDL, and LDL were isolated from each time point and apo B-specific radioactivity was determined as described below.
Laboratory. VLDL (d < 1.006) and LDL (d 1.025-1.060) used for iodination were isolated from plasma by ultracentrifugation as previously described (11) . Each ultracentrifugation was performed at 10C for 20-24 h. All procedures were carried out using aseptic technique and sterilized equipment. The lipoproteins were iodinated by a modification (12) of the iodine monochloride method (13 (17) . Fractions of -10 ml were collected and analyzed for apolipoproteins and lipids. Exact volumes were determined gravimetrically.
Cholesterol and triglyceride concentrations were-measured by specific enzymatic methods using an ABA-100 Analyzer (Abbott Laboratories, Chicago IL). Lipoprotein cholesterol levels were determined after ultracentrifugation according to Lipid Research Clinic methodology (18) , except that dextran sulfate and MgCl2 were used to precipitate the lowerdensity lipoproteins before measurement of HDL cholesterol (19) . This method results in HDL cholesterol concentrations that are -5-10% lower than those obtained using the Lipid Research Clinic method.
Apolipoproteins E, B, Al, CII, and CIII were measured utilizing specific radioimmunoassays (RIA). Details ofthese RIA have been reported elsewhere for apo E, B, Al, and apo CIII (17) . The RIA for apo CII was essentially identical to that described for apo CIII (17) . Apo All was measured by specific RIA in the laboratory of Dr. Ronald Goldberg, University ofMiami School ofMedicine (20) . Apo AIV was determined by RIA in the laboratory of Dr. Charles Bisgaier, Columbia University College of Physicians and Surgeons (21) .
In vitro studies. Measurements of post-heparin plasma LPL and HTGL activities were carried out as previously described (5) . Blood was withdrawn 15 min after injection of 60 U/kg heparin intravenously and the plasma stored at -70'C until assayed. LPL was measured in the presence of a monospecific antibody that inhibits HTGL (22) , whereas HTGL was assayed in the presence of a high salt buffer.
In vitro studies of the activation of LPL by sera were carried out using purified bovine milk LPL, which had a specific activity of55 mmol (24) . Less than 10% of the substrate was hydrolyzed in 60 min at 370C.
Studies of the activation of LPL were also performed using human LPL. Human milk was obtained from the Human Milk Bank, Babies Hospital, Columbia Presbyterian Medical Center, New York City, and acetone-ether powders of the milk-cream were stored at -200C until used. For these studies, LPL activity was measured using 175 Al of a gum arabic stabilized emulsion containing 2.5 Mmols of triglyceride as described by Brown and Baginsky (5). Heat-inactivated serum from normolipidemic controls and the two probands (5-100 ;l) was added to the emulsion which was then incubated at 370C for 60 min. 10 ul of the LPL preparation was then added and the reaction was allowed to proceed at 371C for 60 min. The FFA were extracted as described by Belfrage and Vaughan (25) .
All assays were performed in triplicate. Less than 5% ofthe maximal activity of the human milk LPL preparation in the emulsion that contained control serum (12.2 Mmol FFA released/ml per h) was observed when no serum was added. Additional studies were performed to assess the effect of addition of purified apo CIII and normal HDL to the probands' sera. Purified apo CIII was added to each patients serum to approximate levels present in normal plasma (17) and HDL was added at a final protein concentration 1 mg/ml. After a 30-min preincubation period, these sera were then used in the assay described above to activate human LPL. The maximum LPL activity obtained using the apo CIIIdeficient sera was then compared with that achieved using the same amount of apo CIII-or HDL-repleted sera.
Data analysis. A multicompartmental model of the metabolism of VLDL, IDL, and LDL apo B, based on the simultaneous analysis and modeling program (26) , was used to analyze the tracer data in the present study. The model for the metabolism of VLDL apo B and its subsequent conversion to IDL and LDL was a modification of our earlier model (11) (Fig. 1 ). The decay of '25I-VLDL apo B from the plasma of each of the sisters was characterized by two kinetic components similar to those we have previously observed in other patients (I 1). In addition to these two kinetic subpopulations of plasma VLDL, a third kinetic subpopulation of VLDL particles characterized by an extremely rapid decay rate of '25I-apo B was detected in both subjects. A significant fraction of the apo B radioactivity associated with this third subpopulation was efficiently converted to IDL and LDL. This pathway could account for the rapid appearance of apo B radioactivity that we observed in IDL and LDL (see Results). In addition, the fraction of the injected VLDL apo B radioactivity recovered in LDL was consistently greater than the apo B radioactivity recovered in IDL. These findings suggested that some of the VLDL apo B radioactivity was directly converted to LDL without first contributing to the radioactivity associated with the IDL density fraction. [3H]glycerol. This approach was taken because each subject had an extremely rapid rising component in their curve, suggesting that plasma catabolism was rate limiting for VLDL triglyceride metabolism in these patients. Furthermore, both VLDL triglyceride specific activity curves displayed three-exponential components, kinetic characteristics that were not compatible with the usual compartmental models used by our group and by other investigators ( 1, 15) . Normal patient data, presented for comparison, was determined using our previously described model (15) .
Results
The plasma lipid and apolipoprotein concentrations of the two subjects are presented in Tables I and II. Compared with values for normal subjects reported either in the literature or measured in our laboratory, the patients had reduced plasma levels of 2 Figure 1 . Schematic representation of multicompartmental model describing the metabolism of apo B in VLDL, IDL, and LDL in the two subjects with apo CIII-apo Al deficiency. The majority of apo B flux through VLDL occurs via VI, with the majority of lipoprotein particles passing rapidly from V, to IDL and LDL. Some VLDL apo B enters V2 and is mainly catabolized at a slower rate to IDL and LDL, with a minor fraction passing through V3. Our previous model of apo B metabolism (I 1) did not require pool V, but did include a four-pool cascade to describe the kinetics of apo B metabolism from pool V2 to IDL, and a pathway for transfer of apo B radioactivity from V2 to the very slowly catabolized pool V3. Apo B in pool V3 is not converted to IDL or LDL in either the present or previous model (f1 1). The latter model was used for the analysis of the data from studies in the normal subjects presented in this report. (17) . Offurther interest was the demonstration that the peaks of apo E and apo All in the HDL region did not completely coincide in either patient, suggesting that there might be discrete populations of particles containing one of these apolipoproteins without the other as well as populations with both of these apolipoproteins together. Finally, although there was a peak ofapo CII in the region oftriglyceriderich lipoproteins in each subject, the overall distribution of apo ELUTION VOLUME (ml) Figure 2 . The distribution of apolipoproteins obtained after chromatography of plasma over 4% agarose. The notation, LDL, denotes the position of the low density lipoprotein cholesterol peak in each study, and can be used as an internal marker for comparison of the two studies. Although apo CII has a peak in VLDL, no significant accumulation of apo E is present in that range. In each subject, apo E is distributed in a single peak eluting just in front of the apo All peak. (A) In subject 1, apo CII in HDL is mainly coincidental with the apo E peak; (B) in subject 2, HDL apo CII appears to be much more closely aligned with apo AI.
CII was different in the two sisters. There was a closer association of apo E with apo CII in the HDL region in subject 1 and better concordance for the distributions of apo All and apo CII in subject 2. The basis for this heterogeneity is unknown. However, subject 2 has shown variability of this distribution over time, and a pattern more closely resembling that in subject 1 was observed several months later (27) . The results of apo B turnover studies are depicted in Fig. 3 .
After injection of autologous '25I-VLDL, there was a very rapid decay of radioactivity in VLDL apo B in both subjects followed by rapid conversion of labeled apo B to IDL and LDL (Fig. 3 a  and b) . In contrast to the characteristic biphasic decay of apo B specific activity in VLDL that is observed in a typical study of a normal subject (Fig. 3 c) , each ofthe apo CIII-apo Al-deficient subjects appeared to have three-exponential components oftheir VLDL apo B curves with the additional component being a very rapid early decay. Normal subjects also have a characteristic delay of 3-5 h between the point at which the VLDL and IDL apo B specific activity curves cross and the maxima of the IDL apo B specific activity curve (Fig. 3 c) , but this delay was nearly (Fig. 3 a) or completely (Fig. 3 b) absent in the two patients. Finally, in contrast to the normal time of 15-20 h before the peak LDL apo B specific activity is observed, LDL apo B specific activities reached their peak in <10 h in the studies of the two sisters.
To provide quantitation of the metabolism of VLDL apo B and its conversion to LDL apo B the data were subjected to compartmental analysis. The kinetic parameters describing the metabolism of apo B in these two subjects with apo CIII-apo AI deficiency are presented in Table III . Both subjects had markedly increased FCR for VLDL apo B based on analyses of the '3I1-VLDL apo B specific-activity decay curves-49.1 and 42.0 pools per day, respectively. These rates were six to seven times faster than those present in normolipidemic males we have studied (28) . The Figure 3 . Curves describing the kinetics of apo B specific radioactivity in VLDL, IDL, and LDL during the 48-h period after injection of whole radiolabeled VLDL into (a) subject 1, (b) subject 2, and (c) a normal control subject. Apo B metabolism in both subjects I and 2 is characterized by an extremely rapid early component of VLDL decay; the range of values we have measured in normal control subjects (28) .
Because the very rapid early decay of VLDL apo B in both subjects could have been the results of removal of damaged or "foreign" material by macrophages in liver and spleen, we screened the 1251-VLDL from subject 1 in a cynomolgus monkey.
'3'I-VLDL from a normal control subject was simultaneously injected into the monkey for comparison. The resultant curves for VLDL, IDL, and LDL apo B specific activity were essentially identical (Fig. 4) , arguing against "damage" to the VLDL tracer as the basis for rapid removal in the two sisters.
The turnover of VLDL triglyceride in each subject, determined after the injection of [2-3H]glycerol, was in accord with the rapid catabolism of VLDL apo B (Fig. 5) . Each subject had an extremely rapid rise of radioactivity in plasma followed by a three-exponential decay curve. The peak VLDL triglyceride specific activity was attained by 30 min. This peak is reached in 2-3 h in normal subjects. The first decay component was very rapid in each subject, paralleling the rapid, first decay component present in their VLDL apo B specific-activity decay curves. The FCR for VLDL triglyceride was 2.6 h-' in subject 1 and 0.83 h-' in subject 2. Both of the values were significantly increased compared with values determined in normal subjects in our laboratory (0.33±0.07 h-') (28). The low steady-state levels of plasma VLDL triglyceride were due entirely to the rapid clearance in that the production rates were within normal limits. 
HOURS
In contrast to the rapid rates for VLDL catabolism, the FCR for LDL apo B were normal in both subjects (Table III) . These rates were estimated from the apo B specific activity curves generated by the separate injection of "3tI-LDL. They were in good agreement with the estimated fractional rates derived from analysis of the 1251I-LDL apo B curves generated by the 125I-VLDL injection: 0.49 pools per day for both subjects. Using their respective LDL apo B levels of 85.7 and 85.1 mg/dl, the calculated production rates of LDL apo B were 20.1 and 16.8 mg/kg per d. These rates were moderately elevated compared with those present in our control subjects (28) .
Compartmental analysis of the flow of apo B radioactivity from VLDL through IDL into LDL demonstrated that 62 and 89% of VLDL apo B was converted to LDL in subjects 1 and 2, respectively (Table III) . These values were in the upper range for normal subjects in our laboratory (unpublished data). The more efficient conversion of VLDL apo B into the LDL density range was sufficient to explain the high rates of LDL production in these patients.
Post-heparin plasma LPL and HTGL activities were determined in both subjects. The levels of LPL activity (4.6 and 12.0 Mmol FFA/ml of plasma per h for subjects 1 and 2, respectively) were within the normal range for our laboratory (20.2±8.0). HTGL activity was similarly normal (38.8 and 31.0 vs. 36.6±16.6 emol FFA/ml of plasma per h). These results suggested that the rapid catabolism oftriglyceride-rich lipoprotein in the apo CIII- curves are characterized by a very fast early decay component followed by a biexponential fall in radioactivity. In contrast, the normal curve has a much broader peak of radioactivity followed by a biexponential decay curve.
apo Al patients was not the result of increased presence of LPL or HTGL on the luminal surfaces of endothelial cells.
In vitro experiments were carried out in order to investigate more directly the role of apo CIII deficiency in the rapid catabolism of VLDL observed in vivo. Normal serum, when mixed with an artificial or a natural substrate for measurement of LPL activity, produces activation of the enzyme that reaches a maximum at a volume characteristic of the substrate emulsion and the serum itself. Larger volumes of serum inhibit the hydrolysis of the substrate (4, 5) . When sera from the apo CIII-apo AI patients were compared with normal sera, the results (Fig. 6 A  and B) indicated that the inhibition ofLPL activity was markedly reduced or absent when the sera from the apo CIII-apo AIdeficient subjects were used. Equivalent absolute levels ofactivity were attained when similar optimal volumes ofpatient or control serum were added to the substrate prior to addition ofthe purified bovine milk LPL, demonstrating that there was sufficient apo CII to maximally activate the enzyme even though the apo CII concentrations in the two patients were only about 10% of that in the control serum. However, whereas increasing volumes of normal sera above the level required for maximal activation resulted in inhibition of LPL activity, larger volumes of apo CIII-apo AI-deficient serum had no inhibitory effect. Identical results were obtained in several experiments utilizing either purified human or bovine milk LPL. Addition ofpurified apo CIII to the apo CIII-apo AI-deficient sera, prior to their use as activators, resulted in maximal levels of LPL activity that were 20-50% less than those observed when the native apo CITI-apo AI-deficient sera were used (Fig. 6 C) . In addition, when greater than optimal volumes of apo CIII reconstituted sera were used as activators, further inhibition of LPL activity was demonstrated. In contrast, when normal HDL was added to the apo CIII-apo Al-deficient sera, no effect upon the ability of these sera to activate LPL was demonstrable (Fig. 6 D) .
Discussion
In vitro and in vivo evidence from various laboratories has clearly demonstrated unique roles for several of the plasma apolipoproteins in the regulation ofVLDL, IDL, and LDL metabolism. Genetic disorders of lipoprotein structure and metabolism have given further insights into the functions of these lipid-binding proteins. The role of apo B in VLDL secretion is evident from studies of the recessive disorder abetalipoproteinemia, and its importance in receptor interaction for uptake and degradation of LDL is demonstrated by familial hypercholesterolemia. The lack ofreceptor for apo B, as in the homozygous state offamilial hypercholesterolemia, results in severe premature atherosclerosis (29) . Studies by Rall et al. (30) and Havel (31) have amply demonstrated the importance of apo E for VLDL remnant catabolism, whereas type III hyperlipoproteinemia provides the in vivo model for ineffective interaction of apo E with cell membrane receptors. In vitro studies have also demonstrated the need for apo CII activation ofLPL and the absence ofthis apolipoprotein in certain families with severe hypertriglyceridemia provided the in vivo confirmation for those in vitro studies (32, 33) . Finally, in vitro and in situ studies have suggested two roles for apo CIII. The first is that of an inhibitor of hydrolysis of tri- glyceride-rich lipoproteins by LPL and HTGL (4) (5) (6) , and the second, as an inhibitor of apo E-mediated hepatic uptake of chylomicron remnants and VLDL (7) (8) (9) . The identification of two sisters with apo CIII-apo Al deficiency (1) provided us with a unique opportunity to observe the effects of the absence of apo CIII upon the in vivo metabolism ofthe triglyceride-rich lipoproteins, VLDL and IDL. The results of the kinetic studies presented in this report indicate that apo CIII acts as an inhibitor of in vivo hydrolysis of triglyceride in VLDL and IDL of normal subjects. This inhibitory activity appears to act, at least in part, upon LPL. This conclusion is based on several aspects of our studies.
First, the FCR of both VLDL triglyceride and VLDL apo B were significantly increased in the apo CIII-deficient subjects compared with normal controls. The decay curves ofboth VLDL apo B and VLDL triglyceride demonstrated very rapid early decay components that have not been observed in previous studies of normal or hyperlipidemic individuals. Major proportions of both apo B and triglyceride flux in VLDL occurred via this rapid catabolic pathway. Although the apo CIII-apo Aldeficient subjects had VLDL apo B concentrations that were significantly lower than the levels in our normal subjects, our control subjects were very "normal," with total triglyceride levels near the 10th percentile for their ages. In addition, in a study by Nestel et al. (34) , in which plasma VLDL apo B concentrations were reduced by dietary fish oils to levels comparable to those in our patients, the FCR of VLDL apo B were quite similar to those of our control subjects. It appears quite likely, therefore, that the very rapid FCR for VLDL in the two patients were the cause, rather than the result, of their severely reduced plasma VLDL pools. Increased triglyceride hydrolysis in these subjects is also suggested by the observation of Forte et al. (10) who noted a less than normal increase in plasma triglyceride concentration after a 100-g fat meal in subject 1. Those investigators also noted the appearance of abnormal, nonspherical particles that floated in the LDL density range after the fat meal and suggested that these particles might be abnormal remnants of accelerated hydrolysis of chylomicron particles (10) .
Second, the rapid catabolism of VLDL was associated with an efficient conversion ofVLDL to IDL and ultimately to LDL. This indicated that the rapid turnover of VLDL was not the result of removal of the entire particle from plasma by an endocytic process, but the hydrolysis of the triglyceride core with generation of a more dense product. The demonstration of increased conversion was not simply the result of injection of a VLDL tracer consisting ofsmall VLDL, inasmuch as our patients have a normal size distribution of their VLDL (10) . Third, the similarity between the plasma decay curves of apo CIII-apo AIdeficient VLDL and normal VLDL in the monkey suggested that monkey apo CIII was able to exchange into the apo CIIIdeficient tracer and normalize (slow) its fractional catabolism. Fourth, although studies of VLDL metabolism have demonstrated a correlation between the fractional catabolism of this lipoprotein and LPL activity (35, 36) , assay of post-heparin plasma LPL and HTGL activities did not support the possibility that the two subjects had increased quantities of either of these enzymes available to circulating lipoproteins. Finally, the in vitro studies utilizing the subjects' apo CIII-apo AI-deficient sera as activators for purified bovine and human milk LPL provided strong evidence in support of the role of apo CIII present in normal serum as an inhibitor of LPL induced triglyceride lipolysis.
Although these studies support the proposal that apo CIII inhibits LPL activity in vivo, it is more difficult to draw conclusions concerning the possible role of apo CIII as an inhibitor of apo E-mediated hepatic uptake of triglyceride-rich lipoproteins.
On the one hand, the extremely rapid and efficient conversion of VLDL and IDL to LDL speaks against increased apo E-mediated receptor removal of triglyceride-rich lipoprotein particles in the two subjects. However, the high degree of conversion to LDL in our two subjects does not rule out the possibility that in normal subjects with slower hydrolysis of VLDL and IDL, the uptake of apo E-enriched remnant particles may be modulated by their apo CIII content. The near absence of any VLDL remnant pool in our two subjects (10) would make it very difficult to demonstrate the effect of the absence of apo CIII upon the metabolism of such a pool. Thus, nearly all of the apo E was in the HDL region (Fig. 1) . In addition, Forte and co-workers (10) demonstrated that a large proportion of apo E in HDL was complexed to apo All. This might reduce the apoE available to the patients' VLDL particles and limit apo E-mediated uptake of their VLDL by hepatocytes (10) . The issue is complicated further by the demonstration that apo CI and apo CII also inhibit hepatic uptake of chylomicron and VLDL remnants (37) . The apo CI levels in VLDL were not measured in this study but plasma apo CI levels have been reported to be '40% of normal in the apo CIII-apo AI-deficient subjects. Plasma apo CII concentrations were 10% of normal (Table II) . It is possible that the presence ofthese apolipoproteins on the subjects' VLDL could have minimized the consequences of the absence of apo CIII relative to hepatic uptake of VLDL remnants. Our results also do not directly address possible inhibition, in vivo, ofHTGL by apo CIII. Although Kinnunen and Enholm (6) have demonstrated that apo CIII inhibits HTGL activity in vitro, apo CI and apo CII appear to be equivalent to apo CIII in this regard (6) .
Whether or not apo CIII regulates remnant removal in normal subjects, the rapid and efficient hydrolysis of VLDL triglyceride and the subsequent efficient conversion ofthose VLDL to LDL in these apo CIII-deficient subjects, may have contributed to their precocious arteriosclerosis. Thus, in addition to the near absence of HDL in the two sisters, they had decreased direct removal ofVLDL by hepatocytes. This catabolic pathway, which exists in both normal (38) and hypertriglyceridemic (1 1, 38) subjects, restricts the percentage of VLDL that is converted to LDL. The high LDL production rates present in the apo CIIIdeficient subjects as a consequence of more efficient conversion of VLDL may have further potentiated their risk for vascular disease associated with the near absence ofHDL (39) . In addition, the presence of cholesterol-poor LDL in the two sisters with quite average apo B levels was similar to the LDL composition found in men with coronary artery disease and hyperapobetalipoproteinemia (40) .
The studies in these patients have also provided unique information relative to the roles of apo CII in the regulation of VLDL metabolism. Thus, although apo CII levels in plasma were 5-10% of normal, in vivo fractional catabolism of VLDL was very rapid. In vitro studies, furthermore, indicated that similar volumes of serum from patients and the control subjects produced similar maximal hydrolysis by bovine milk LPL. These data support the view that very little apo CII is needed to maximally activate LPL. This view is also supported by the studies ofkindreds with apo CII deficiency in which heterozygotes, with 30-50% normal levels of apo CII had normal plasma triglyceride concentrations (32, 33 On the other hand, the abnormal HDL profile present in these subjects suggests that apo AI may be necessary for orderly HDL metabolism. The chromatographic studies demonstrated the presence of populations of particles in the HDL size range with apo E, apo CII, and apo All in varying proportions. In fact, there appeared to be some particles with only apo E and apo CII present, others with only apo CII and apo All present, and even others with all ofthese three apolipoproteins as components. The source of the apo E and apo CII in the HDL region would appear to be the hydrolysis ofVLDL and IDL with concomitant transfer of these two apolipoproteins and surface lipids to an HDL particle containing apo All as the major protein. However, the significant reductions in the plasma levels of apo CII, apo E, and apo All in the two sisters, together with the very rapid fractional removal of their autologous, radiolabeled HDL (unpublished observations), indicate that apo Al and/or apo CIII may be necessary to stabilize plasma HDL particles and prolong their residence time in the extracellular space. Alternatively, the rapid catabolism of their HDL may result from the presence of apo E on a large majority of particles (41) . Regardless of the mechanism, the markedly shortened time of residence ofplasma HDL in these two sisters was associated with severe, premature arteriosclerosis.
